| The problem of Ivermectin trials based in Latin American countries is that community Ivermectin use is so widespread, it becomes a major confounder in trials because most of the 'placebo' group could be using it. 'Latin America’s embrace of an unproven COVID treatment is hindering drug trials' https://www.nature.com/articles/d41586-020-02958-2 Hopefully it would be noted in the limitations section of the trial paper, but the writers of media articles are often polarized or biased and just cherry pick. ETA, personally I would prefer small well designed trials from researchers with historical expertise who provide plenty of accompanying information and are willing to discuss the results, eg Chaccour et al: 'The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial' https://www.thelancet.com/journals/eclinm/article/PIIS2589-5... https://www.youtube.com/watch?v=yIUO08W94eY
https://www.youtube.com/watch?v=JuzHG0rpOrc |